Latest Pharma and Biotech News
Pharmaceutical
15 April 2025 Shares in Johnson & Johnson were 1% lower in the early stages of Tuesday’s trading after the US health conglomerate presented its first-quarter 2025 financial results.
Today's issue
Refine Search
Pharmaceutical
US biotech Wayfinder Biosciences has entered a research collaboration with Japanese drugmaker Daiichi Sankyo to develop small molecule therapies targeting RNA in neurodegenerative diseases. 16 April 2025
Pharmaceutical
Italian pharma major Recordati today announced that the US Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) for Isturisa (osilodrostat) for the treatment of endogenous hypercortisolemia in adults with Cushing’s syndrome for whom surgery is not an option or has not been curative. 16 April 2025
Pharmaceutical
French drugmaker Ipsen today presented sales for the first quarter of 2025. The company did not release any earnings figures. 16 April 2025
Pharmaceutical
UK pharm major GSK has breached the ABPI Code of Practice for the Pharmaceutical Industry and brought discredit upon, and reduced confidence in the pharmaceutical industry, the trade group’s Prescription Medicines Code of Practice Authority (PMCPA) has revealed. 16 April 2025
Pharmaceutical
US President Donald Trump has passed an executive order that answers the pharmaceutical industry’s calls for the scrapping of the Inflation Reduction Act’s (IRA) ‘pill penalty’. 16 April 2025
Pharmaceutical
Dutch specialty pharma firm Norgine Pharmaceuticals has entered into a definitive agreement to acquire Theravia, a French pharmaceutical company specializing in cutting-edge treatments for patients with rare and debilitating conditions from Mérieux Equity Partners. 16 April 2025
Pharmaceutical
German biotech HepaRegeniX has raised 21.5 million euros ($23 million) in new funding to support the clinical development of its lead candidate, HRX-215, a first-in-class treatment aimed at enhancing liver regeneration. 15 April 2025
Pharmaceutical
Danish pharma major Novo Nordisk says that it has become aware of several hundred units of Ozempic (semaglutide) injection 1 mg distributed outside its authorized supply chain in the USA. 15 April 2025
Pharmaceutical
Cambridge, USA-based biotech Oak Hill Bio, which is focused on acquiring and developing life-changing rare disease therapeutics, has entered into an exclusive license agreement with Roche to obtain global rights for rugonersen (RO7248824). 15 April 2025
Pharmaceutical
Shares in Johnson & Johnson were 1% lower in the early stages of Tuesday’s trading after the US health conglomerate presented its first-quarter 2025 financial results. 15 April 2025
Pharmaceutical
New research from consultancy Vital Transformation has shown the effects of US policy the Inflation Reduction Act’s (IRA) drug pricing provisions on biopharmaceutical investment, research and development (R&D). 15 April 2025
Pharmaceutical
US pharma major Bristol Myers Squibb yesterday disclosed that its Phase III ODYSSEY-HCM trial of Camzyos (mavacamten) did not meet its primary endpoints for treating non-obstructive hypertrophic cardiomyopathy (nHCM). 15 April 2025
Pharmaceutical
US gastrointestinal (GI) and rare diseases specialist Ironwood Pharmaceuticals was trading 34% lower early Monday. 14 April 2025
Pharmaceutical
Japan’s RaQualia Pharma has announced the termination of the license agreement regarding a retinoic acid receptor agonist (tamibarotene/TM-411/SY-1425, between the USA’s Syros Pharmaceuticals and TMRC Co, a consolidated subsidiary of RaQualia. 14 April 2025
Pharmaceutical
US pharma giant Pfizer has announced that it is discontinuing development of danuglipron (PF-06882961), an oral glucagon-like peptide-1 (GLP-1) receptor agonist, which was being investigated for chronic weight management. 14 April 2025
Pharmaceutical
The Dutch Healthcare Authority (NZa) has published a report entitled From patent to competition – Analysis of expenditure and use of seven expensive medicines in hospital treatments. 14 April 2025
Pharmaceutical
Japanese biotech Prism BioLab has entered a strategic partnership with AI drug discovery company Elix to accelerate the development of small molecule therapies for difficult-to-treat diseases. 14 April 2025
Pharmaceutical
New regulations for running clinical trials in the UK have now been signed into law, the Medicines & Healthcare products Regulatory Agency (MHRA) announced on Friday. 14 April 2025
Pharmaceutical
According to the country’s trade group LIF, Sweden must be a driving force in the European Union (EU) to ensure that pharmaceuticals continue to be exempt from tariffs and that a negotiated solution with the US must be reached. 14 April 2025
All news
Pharmaceutical
KalVista Pharmaceuticals shares, which closed Monday at $16.04, were recently up 37% to $22 in pre-market activity, but fell back almost 13% to $14.01 by late morning today, after it released new research data. 13 February 2024
Pharmaceutical
Japanese pharma major Takeda has announced that the US Food and Drug Administration (FDA) has approved Eohilia (budesonide oral suspension), the first and only FDA-approved oral therapy for people 11 years and older with eosinophilic esophagitis (EoE). 13 February 2024
Pharmaceutical
Shares of Japanese drugmaker Otsuka Pharmaceutical fell more than 5% to 5,359 yen today, as it released top line results of the Phase III clinical trial of AVP-786 in the treatment of agitation associated with dementia due to Alzheimer's disease. 13 February 2024
Pharmaceutical
The Yellow Card Biobank, a pilot launched by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) and Genomics England, is to start investigating a group of medicines used to prevent strokes known as direct oral anticoagulants (DOACs). 13 February 2024
Pharmaceutical
The European Commission (EC) has authorized Biogen’s Skyclarys (omaveloxolone) for the treatment of Friedreich’s ataxia (FA) in adults and adolescents aged 16 years and older. 13 February 2024
Pharmaceutical
Foghorn Therapeutics has announced that its partner, Eli Lilly has selected FHD-909, a first-in-class oral BRM selective inhibitor, for clinical development. 12 February 2024
Pharmaceutical
The USA-based AMR Industry Alliance conducted a review of publicly available data on the state of antimicrobial resistance (AMR) research and development talent. 12 February 2024
Pharmaceutical
CymaBay Therapeutics’ shares surged 24.5% to $31.99 pre-market, on the news of an acquisition bid from US major Gilead Sciences. 12 February 2024
Pharmaceutical
Danish drugmaker Lundbeck has its eye on steady growth over the medium term, a strategy which new chief executive Charl van Zyl believes could be key to the firm’s future success. 12 February 2024
Pharmaceutical
UK-based Poolbeg Pharma has announced that research conducted on its behalf confirms a market opportunity of at least $10 billon for POLB 001 in cancer immunotherapy-induced cytokine release syndrome (CRS) as an orally-delivered preventative therapy. 12 February 2024
Pharmaceutical
Spanish plasma-derived products specialist Grifols has announced that Raimon Grifols and Víctor Grifols Deu have chosen to step down from their executive functions – chief corporate officer and chief operating officer, respectively. 12 February 2024
Pharmaceutical
The European Medicines Agency’s (EMA) Pharmacovigilance Risk Assessment Committee (PRAC) is reminding healthcare professionals of the risk of serious and potentially fatal adverse reactions with the COVID-19 treatment Paxlovid (nirmatrelvir and ritonavir). 9 February 2024
Pharmaceutical
Japan’s largest drugmaker Takeda Pharma has announced positive top-line results from a randomized, double-blind, placebo-controlled, multiple dose Phase IIb trial evaluating TAK-861, an oral orexin receptor 2 (OX2R) agonist, in patients with narcolepsy type 1. 9 February 2024
Pharmaceutical
Vicor Pharma has entered into an exclusive licensing agreement with Japan’s Nippon Shinyaku, for the commercialization and development of its C21 idiopathic pulmonary fibrosis (IPF) drug candidate in Japan. 9 February 2024
Pharmaceutical
Despite posting positive clinical trial results for its resmetirom, being trialled in the treatment of non-alcoholic steatohepatitis (NASH,) US drug developer Madrigal Pharmaceuticals saw its shares close down more than 9% at $173.71 yesterday. 9 February 2024
Pharmaceutical
Californian biotech Corvus Pharmaceuticals has appointed Jeffrey Arcara as chief business officer. 8 February 2024
Pharmaceutical
In an Expert View piece, Mark Seymour, Director and Head of Media, Healthcare, at FleishmanHillard London, argues that in the ever-evolving world of healthcare, the rules of communications have not changed, they have just become more intricate, demanding a renewed focus on the essentials. 8 February 2024
Pharmaceutical
Anglo-Swedish pharma major AstraZeneca was trading 5% lower at lunchtime in London on Thursday. 8 February 2024
Pharmaceutical
The USA’s Federal Trade Commission yesterday issued a comment in response to the National Institute of Standards and Technology’s (NIST) request for information on its Draft Interagency Guidance Framework for Considering the Exercise of March-In Rights under the Bayh-Dole Act. 7 February 2024
Pharmaceutical
French pharma major Sanofi has announced that Rippon Ubhi has been appointed as country lead for the UK and Ireland, taking over immediately from Jessamy Baird. 7 February 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze